Amgen, Arrakis Therapeutics partner to develop oral drugs that eliminate troublesome RNA

Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively destroy RNA molecules that turn genetic instructions into disease-causing proteins.

Called “targeted RNA degraders,” this emerging technology will go after targets that traditional drug-development methods can’t reach.

And by selectively eliminating troublesome RNA, this new drug class could theoretically stop any disease-causing protein from being made, no matter where it’s produced in the body, said Ray Deshaies, senior vice president of global research at Amgen.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In